First-line therapy prescriptions in azerbaijan: results from the european registry on helicobacter pylori management (HP-eureg)
Abstract
Background. Gastric lesions associated with Helicobacter pylori, eradication issues in terms of the choice of antibiotics and duration of therapy continue to remain one of the most pressing topics in modern healthcare. Methods. Data were collected from the European Registry on Helicobacter pylori Management (Hp-EuReg) and quality reviewed from January 2020 to May 2023 at AEG-REDCap. All treatment-naïve cases were assessed for choice of regimens and duration, as well as dosing of proton pump inhibitor therapy. Results. The study included 3,898 patients (67% reported dyspepsia). Triple regimens were most often prescribed (82%), the PPI-clarithromycin-amoxicillin scheme being used in 54% of patients. Duration of treatment was of 14 days (56%), 10 days (27%) and 7 days (17%). Conclusion. The prescribed H. pylori eradication regimens during the period 2020–2023 in Azerbaijan adhered partially to the Maastricht recommendations.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.